Scar News and Research

RSS

BioVentrix uses Revivent system for LIVE procedure in Germany

BioVentrix, a pioneer of technologies and procedures for the less-invasive treatment of heart failure (HF), today announced the successful first-use of its Revivent™ Myocardial Anchoring System, via Less Invasive Ventricular Enhancement™ or the LIVE™ procedure in Germany.

13 Aug 2013

Gene combination therapy repairs and prevents future damage of muscles caused by DMD

New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused by Duchenne muscular dystrophy, but also prevents future injury from the muscle-wasting disease.

12 Aug 2013

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.

8 Aug 2013

Study: Stem cells in mouth tissue can relieve inflammatory disease

Stem cells found in mouth tissue can not only become other types of cells but can also relieve inflammatory disease, according to a new Ostrow School of Dentistry of USC study in the Journal of Dental Research.

5 Aug 2013

Trace substance in sugar improves muscle regeneration in mouse model with muscular dystrophy

A trace substance in caramelized sugar, when purified and given in appropriate doses, improves muscle regeneration in a mouse model of Duchenne muscular dystrophy. The findings are published today, Aug. 1, in the journal Skeletal Muscle.

2 Aug 2013

Researchers show that JQ1 drug can block molecular pathway responsible for heart failure

Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.

2 Aug 2013

Novo Solutions MD announces releases of NovoScarMD scar cream

Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury

25 Jul 2013

Mechanical tension increases nerve density, nerve growth factor expression in scar tissue

Scars are prone to appear at high tension parts, such as the sternum, shoulder and back, which are serious clinical problems. Surgeons reduce scar formation through Z, W, V-Y flap variation and reducing blade tension, but its specific mechanism are still not very clear.

25 Jul 2013

Incentives for Ontario surgeons drive greater use of laparoscopic colon cancer surgery

Financial incentives for Ontario surgeons are likely a key factor driving greater use of laparoscopic colon cancer surgery, says a study led by a McMaster University surgeon.

23 Jul 2013

Study leads to new approach for treatment of aortic valve stenosis

A study conducted by the team of Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, has led to the discovery of a new approach to treat aortic valve stenosis through the administration of a compound that prevents valve deterioration and can even reverse the progression of the disease.

19 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

New noninvasive technique for tracking stem cells after transplantation

A new, noninvasive technique for tracking stem cells after transplantation - developed by a cross-disciplinary team of radiologists, chemists, statisticians and materials scientists at the Stanford University School of Medicine - could help surgeons determine whether a procedure to repair injured or worn-out knees is successful.

12 Jul 2013

Spanish doctors perform more than 1,500 POSE weight loss procedures

Spanish doctors are leading the way by performing more than 1,500 procedures of the scar-free, non invasive, weight loss method of Primary Obesity Surgery, Endolumenal, known as POSE. Over thirty Spanish doctors have now performed more cases in Spain (where 1 in 6 people are obese) than in any other part of the world.

8 Jul 2013

Scientists track down origins of fibrosis-promoting cells that scar and destroy organs

Scientists have tracked down and quantified the diverse origins of cells that drive fibrosis, the incurable, runaway wound-healing that scars and ultimately destroys organs such as the lungs, liver and kidneys.

2 Jul 2013

New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.

30 Jun 2013

Dallas plastic surgeon offers Natrelle 410 silicone breast implant to select patients

Dallas plastic surgeon Dr. Fred Hackney announced today that he is now offering the Natrelle 410 highly cohesive silicone breast implant to select patients. Commonly called the "gummy bear implant" because of its texture, these implants have recently been approved by the FDA for use by qualified, board-certified plastic surgeons.

27 Jun 2013

Study describes molecular bases of resistance to new chemotherapeutic agent in familial breast and ovarian cancers

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2.

19 Jun 2013

MHN, Auxilium Pharmaceuticals launch new health awareness program on Peyronie's disease

Men's Health Network and Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, have announced the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease and to help empower men to have meaningful discussions about their condition with their partner and their healthcare provider.

11 Jun 2013

New research proves value of PET/MR compared to PET/CT in cardiac applications

Just a few years ago, integrated positron emission tomography and magnetic resonance (PET/MR) imaging was found only in research institutes, but little by little the technology has expanded into clinical practice.